🇺🇸 FDA
Pipeline program

OPC-34712

331-08-210

Phase 2 small_molecule completed

Quick answer

OPC-34712 for Schizophrenia is a Phase 2 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
Otsuka Beijing Research Institute
Indication
Schizophrenia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials